Description

Adcitris 50mg Injection (Brentuximab) Uses, Dosage, Side Effects & Availability in Pakistan

Adcitris 50mg Injection (Brentuximab) contains brentuximab vedotin, a targeted cancer medicine used for certain types of lymphoma. It is designed to target CD30-positive cancer cells and is administered as an intravenous infusion by a qualified healthcare professional.

Because Adcitris is an oncology medicine, treatment should only be given under the supervision of an experienced oncologist after the patient’s diagnosis and treatment requirements have been assessed.

What Is Adcitris 50mg Injection?

Adcitris 50mg Injection contains brentuximab vedotin, an antibody-drug conjugate that targets the CD30 protein found on certain lymphoma cells. The 50mg strength is supplied as a powder that must be reconstituted and prepared for intravenous infusion.

Brentuximab vedotin combines a CD30-directed monoclonal antibody with a microtubule-disrupting agent called monomethyl auristatin E (MMAE). After binding to CD30-positive cells, the medicine is taken into the cell and releases MMAE, which interferes with cell division and can lead to cancer-cell death.

Adcitris 50mg Uses

Brentuximab vedotin is used for certain CD30-positive lymphomas, including Hodgkin lymphoma and some types of non-Hodgkin lymphoma. The exact indication depends on the patient’s diagnosis, disease stage and previous treatment.

Hodgkin Lymphoma

Adcetris is used in adults with certain forms of Hodgkin lymphoma, including some previously untreated advanced CD30-positive disease and relapsed or refractory disease. It may be used alone or in combination with other cancer medicines depending on the treatment setting.

It can also be used in certain patients who have undergone an autologous stem cell transplant and are considered at increased risk of relapse or progression.

Systemic Anaplastic Large Cell Lymphoma

Brentuximab vedotin is also used for adults with systemic anaplastic large cell lymphoma (sALCL). It may be used with combination chemotherapy in previously untreated patients or as treatment for relapsed or refractory disease.

Cutaneous T-Cell Lymphoma

In the European Union, Adcetris is indicated for adults with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one previous systemic therapy.

The appropriate use of brentuximab depends on the approved indication in the relevant country and the individual patient’s clinical condition.

How Does Brentuximab Vedotin Work?

Brentuximab vedotin is a CD30-directed antibody-drug conjugate. The antibody component attaches to CD30 on certain cancer cells. After the medicine enters the cell, MMAE is released and interferes with microtubules, structures that are important for cell division. This can stop cancer cells from dividing and may lead to their death.

This targeted mechanism allows brentuximab vedotin to specifically act on cells expressing CD30.

Adcitris 50mg Dosage

The dosage of brentuximab vedotin depends on the specific cancer being treated, whether it is being used alone or with other medicines, the patient’s body weight and overall health.

For several adult indications, the commonly used dose is 1.8 mg/kg administered intravenously every three weeks, although different treatment settings may have different dosing schedules.

Because dosing can vary according to the indication and treatment combination, the dose should always be calculated and administered by the treating oncology team.

Do not self-administer Adcitris or attempt to prepare the injection at home.

How Is Adcitris 50mg Injection Given?

Adcitris is given as an intravenous infusion after the powder has been properly reconstituted and diluted by trained healthcare professionals. The medicine is not intended for self-injection.

Your healthcare team will determine the infusion schedule based on your cancer type and treatment plan.

If an infusion reaction develops, the healthcare professional may interrupt the infusion and provide appropriate treatment.

Adcitris Side Effects

Like other cancer medicines, brentuximab vedotin can cause side effects. Some commonly reported adverse effects may include:

• Peripheral neuropathy
• Fatigue
• Nausea
• Diarrhea
• Vomiting
• Fever
• Reduced appetite
• Abdominal pain
• Headache
• Upper respiratory tract infections
• Changes in blood-cell counts

The type and severity of side effects can vary depending on whether brentuximab is used alone or with other cancer medicines.

Serious Side Effects and Warnings

Peripheral Neuropathy

Brentuximab vedotin can cause peripheral neuropathy, which may result in numbness, tingling, burning sensations or weakness, particularly in the hands and feet. Healthcare professionals should monitor patients for neurological symptoms and may modify treatment when necessary.

Infusion Reactions and Anaphylaxis

Serious infusion-related reactions, including anaphylaxis, can occur. Patients are monitored during and after administration, and treatment may need to be interrupted or discontinued if a severe reaction occurs.

Lung Toxicity

Brentuximab has been associated with serious pulmonary reactions. Patients should promptly report new or worsening breathing problems, cough or other respiratory symptoms to their healthcare team.

Serious Infections

Treatment may increase the risk of infections, particularly when combined with other medicines that suppress the immune system. Fever or other signs of infection should be reported promptly.

Progressive Multifocal Leukoencephalopathy

Rare cases of progressive multifocal leukoencephalopathy (PML) have been reported with brentuximab vedotin. New neurological symptoms should be assessed urgently by a healthcare professional.

Adcitris Drug Interactions

Before receiving Adcitris, inform your doctor about all medicines, supplements and herbal products you are taking.

Brentuximab vedotin can interact with medicines that affect certain metabolic pathways, and the risk of side effects may increase when it is combined with other treatments that can cause similar toxicities.

Importantly, brentuximab vedotin should not be given together with bleomycin because of the risk of pulmonary toxicity.

Your oncologist should review your complete medication list before treatment.

Adcitris 50mg Injection During Pregnancy and Breastfeeding

Brentuximab vedotin may cause fetal harm. Patients who are pregnant, planning pregnancy or able to become pregnant should discuss appropriate contraception and treatment risks with their healthcare professional.

The U.S. prescribing information advises patients to avoid breastfeeding while receiving Adcetris.

Patients should inform their oncologist if pregnancy occurs during treatment.

Storage of Adcitris 50mg Injection

The U.S. product labeling states that Adcetris vials should be stored at 2°C to 8°C in the original carton to protect them from light.

The medicine requires professional preparation and handling before intravenous administration. Always follow the storage requirements provided with the specific product packaging.

Adcitris 50mg Availability in Pakistan

Adcitris 50mg Injection (Brentuximab) is available in Pakistan through imported medicine suppliers, subject to current stock and supplier availability. The product is listed as an imported oncology medicine and is available for delivery across Pakistan.

For the latest Adcitris 50mg availability in Pakistan, customers can contact Impo Medic directly to confirm stock status and ordering details.

As Adcitris is a prescription oncology medicine, it should only be used and administered under the supervision of a qualified healthcare professional.

Adcitris 50mg Price in Pakistan

The price and availability of Adcitris 50mg Injection (Brentuximab) in Pakistan may vary depending on supplier availability, import conditions and market factors.

For the latest Adcitris 50mg price and availability in Pakistan, customers can contact Impo Medic directly before placing an order.

As Adcitris is a prescription oncology medicine, it should only be used according to a qualified healthcare professional’s treatment plan.

Why Choose Impo Medic?

At Impo Medic, our goal is to make access to specialized medicines easier while providing clear product information.

• Information about medicine strength and active ingredients
• Assistance with product availability
• Convenient online ordering support
• Focus on specialized and oncology medicines
• Customer support for product-related queries

Patients should confirm the required medicine, strength and treatment plan with their healthcare professional before ordering.

FAQs About Adcitris 50mg Injection (Brentuximab) Imported

1. What is Adcitris 50mg Injection used for?

Adcitris contains brentuximab vedotin and is used for certain CD30-positive lymphomas, including specific forms of Hodgkin lymphoma, systemic anaplastic large cell lymphoma and cutaneous T-cell lymphoma.

2. What is the active ingredient in Adcitris?

The active ingredient is brentuximab vedotin. Each Adcetris vial contains 50mg of brentuximab vedotin.

3. How is Adcitris 50mg given?

Adcitris is prepared and administered as an intravenous infusion by trained healthcare professionals.

4. What are common Adcitris side effects?

Possible side effects include peripheral neuropathy, fatigue, nausea, diarrhea, vomiting, fever and changes in blood-cell counts.

5. Can Adcitris be used with chemotherapy?

Yes. Depending on the approved indication, brentuximab vedotin may be administered with other cancer medicines as part of a combination treatment regimen.

6. Can Adcitris be given with bleomycin?

No. Concomitant use with bleomycin is contraindicated because of the risk of pulmonary toxicity.

7. Is Adcitris a chemotherapy medicine?

Brentuximab vedotin is a targeted antibody-drug conjugate. It delivers a cytotoxic component to CD30-positive cells rather than functioning like conventional chemotherapy alone.

8. Can I use Adcitris without a prescription?

No. Adcitris is a prescription oncology medicine and should only be administered under the supervision of a qualified healthcare professional.

Medical Disclaimer

This article is provided for general educational purposes only and does not replace advice from an oncologist, doctor or pharmacist. Adcitris (brentuximab vedotin) should only be used according to a healthcare professional’s prescription and treatment plan. Do not change, start or stop cancer treatment without medical advice.